Swiss Biotech Stock News

Sika (SWX:SIKA) is back in focus after its 2025 trading update showed weaker sales, a lower profit margin outlook, and a sharp share price reaction as investors reassess regional and currency risks. See our latest analysis for Sika. The recent 2025 trading update and guidance cut come on top of a weaker share price trend, with a 90 day share price return of 14.17% and a 1 year total shareholder return of 32.05%. This points to fading momentum as investors reassess regional and currency...

Asmallworld AG ( VTX:ASWN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

ARYZTA AG's ( VTX:ARYN ) price-to-earnings (or "P/E") ratio of 12.8x might make it look like a buy right now compared...

Despite an already strong run, Comet Holding AG ( VTX:COTN ) shares have been powering on, with a gain of 33% in the...

Why Roche Holding (SWX:ROG) is on investors’ radar today Roche Holding (SWX:ROG) is drawing attention after recent share price moves, with the stock last closing at CHF 348.90 and showing double digit returns over the past month and past 3 months. For investors, that combination of recent performance and the company’s sizeable pharmaceuticals and diagnostics footprint raises the question of how the current price lines up with its fundamentals and value characteristics. See our latest analysis...

Recent performance snapshot Nestlé (SWX:NESN) has been under pressure recently, with the share price showing a 1-day decline of 1.67% and a roughly 5% decline over the past month. See our latest analysis for Nestlé. At a share price of CHF75.24, Nestlé’s recent 30-day share price decline of about 5% and 90-day share price decline of about 11% contrast with a 1-year total shareholder return of roughly 5%. This suggests that near term momentum is fading while longer term returns remain...

In mid-January 2026, Galderma presented new clinical data on its neuromodulator portfolio Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid, alongside a dedicated Relfydess Masterclass led by expert physicians and its Global Head of R&D. The strong responder rates, extended median time to baseline, and head-to-head diffusion data for Relfydess highlighted scientific differentiation that Galderma is using to reinforce its position in injectable aesthetics. We’ll now...

Why Cosmo Pharmaceuticals is Back on Investors’ Radars Cosmo Pharmaceuticals (SWX:COPN) is drawing fresh attention after management detailed a scale up phase under its Vision 2030 plan, highlighting solid finances, expanding GI Genius and Winlevi franchises, and a maturing dermatology and gastroenterology pipeline. See our latest analysis for Cosmo Pharmaceuticals. That story around Vision 2030 seems to be resonating with the market, with a 90 day share price return of 75.23% and a 1 year...

Julius Bär Gruppe has announced past and upcoming organisational and leadership changes, appointing former HSBC executive Jean Nabaa as COO while current COO and Deputy CEO Nic Dreckmann plans to step down by April 2026, alongside the creation of a new Group Communications function to be led by experienced communicator Cindy Leggett-Flynn. By bringing in leaders with extensive international wealth management and high-stakes communications experience, Julius Bär is signaling a push to...

What the new Pfandbrief institute means for Liechtensteinische Landesbank investors Lichtensteinische Landesbank (SWX:LLBN) has partnered with LGT to launch the Liechtensteinisches Pfandbriefinstitut, giving the local market its first platform for issuing covered bonds backed by first lien mortgages. See our latest analysis for Liechtensteinische Landesbank. Alongside the new Pfandbrief institute, Liechtensteinische Landesbank’s share price return has been positive in recent months, with a 7...

Why Zurich Insurance Group’s risk warnings are back in focus Zurich Insurance Group (SWX:ZURN) is back on investors’ radar after senior executives highlighted rising geopolitical, technological, and societal risks, ahead of the group’s upcoming presentation at the Octavian Seminar 2026 in Davos. See our latest analysis for Zurich Insurance Group. Zurich’s share price at CHF 578.8 has slipped over the year to date, yet a 90 day share price return of 4.25% sits alongside a 1 year total...

Novartis (SWX:NOVN) is back in focus as investors look ahead to the 4 February 2026 earnings report and consider fresh capital allocation comments from the CEO on acquisitions and business development. See our latest analysis for Novartis. The recent flurry of business development deals, radioligand therapy investments and talk of further oncology focused acquisitions has gone hand in hand with a 6.51% 30 day share price return and a 30.89% 1 year total shareholder return, suggesting momentum...

As European markets continue to show optimism with major stock indexes rising, investors are increasingly focused on the strengthening eurozone economy and favorable interest rate conditions. In this environment, dividend stocks can offer a stable income stream, making them an attractive option for those looking to capitalize on the current economic momentum while potentially benefiting from regular payouts.

Avolta AG ( VTX:AVOL ), is not the largest company out there, but it saw a double-digit share price rise of over 10% in...

Forbo Holding AG ( VTX:FORN ), is not the largest company out there, but it saw a significant share price rise of 34...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

There wouldn't be many who think CALIDA Holding AG's ( VTX:CALN ) price-to-sales (or "P/S") ratio of 0.4x is worth a...

Most readers would already be aware that Ascom Holding's (VTX:ASCN) stock increased significantly by 16% over the past...

DKSH Holding AG recently received official validation from the Science Based Targets initiative that its near-term and net-zero emissions targets align with climate science and the Paris Agreement, confirming deep reductions in Scope 1, 2, and 3 emissions and a commitment to net-zero across its value chain by 2050. This independent endorsement strengthens DKSH’s sustainability positioning, underscoring how its efforts in transport optimization, renewable electricity, fleet electrification,...

If you are wondering whether Roche Holding's current share price really reflects its quality and prospects, you are not alone; many investors are asking the same question. The stock last closed at CHF 345.70, with returns of 1.9% over 7 days, 7.9% over 30 days, 6.2% year to date, 33.0% over 1 year and 31.0% over 3 years. This naturally raises questions about how much of this performance is already priced in. Recent coverage has focused on Roche Holding's position as a major global...

Earlier this month, UBS Group AG completed two US$1.50 billion fixed-coupon, perpetual, callable subordinated Eurobond issues, while simultaneously intensifying its public opposition to proposed tighter Swiss banking capital rules following the Credit Suisse collapse. By arguing that fully capitalizing foreign subsidiaries and raising capital buffers could add about US$1.70 billion in annual costs and threaten its business model, UBS has put the trade-off between financial stability and...

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Sika AG recently reported preliminary 2025 results showing CHF 11.20 billion in sales, modest growth in local currencies but a reported sales decline due to a strong Swiss franc, softer construction demand in markets such as China and the US, and an earnings margin outlook now only slightly above 19% excluding one-off restructuring costs. Management launched the “Fast Forward” cost and investment program, including up to 1,500 job cuts and targeted annual savings of CHF 150–200 million by...